Immunocore says Phase 1 brenetafusp data show 87% 6-month survival in advanced melanoma patients

• Immunocore presented updated Phase 1/2 results for brenetafusp in heavily pretreated advanced melanoma at the 2026 ASCO Annual Meeting.
• The study showed meaningful survival and disease control signals in patients who had progressed on prior PD-1 therapy.
• Findings supported selecting the 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 first-line advanced melanoma trial.
• Activity appeared consistent in difficult-to-treat patients, including those with primary resistance to PD-1 therapy.
• Safety was described as generally tolerable, with side effects characterized as predictable and manageable across monotherapy and combination use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605310800PRIMZONEFULLFEED1001184620) on May 31, 2026, and is solely responsible for the information contained therein.